134 related articles for article (PubMed ID: 37580397)
1. Abatacept for graft versus host disease prophylaxis in patients 60 years and older receiving mismatched unrelated donor transplantation for hematologic malignancies.
Raghunandan S; Qayed M; Watkins BK; Graiser M; Gorfinkel L; Westbrook A; Gillespie S; Bratrude B; Petrovic A; Suessmuth Y; Horan J; Kean LS; Langston AA
Bone Marrow Transplant; 2023 Nov; 58(11):1264-1266. PubMed ID: 37580397
[No Abstract] [Full Text] [Related]
2. Abatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis.
Raghunandan S; Gorfinkel L; Bratrude B; Suessmuth Y; Hebert K; Neuberg D; Williams KM; Schoettler ML; Langston AA; Kean LS; Qayed M; Horan J; Watkins BK
Bone Marrow Transplant; 2023 Nov; 58(11):1260-1263. PubMed ID: 37580396
[No Abstract] [Full Text] [Related]
3. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
[TBL] [Abstract][Full Text] [Related]
4. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402
[TBL] [Abstract][Full Text] [Related]
5. Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies.
Konuma T; Kato S; Oiwa-Monna M; Ishii H; Tojo A; Takahashi S
Leuk Lymphoma; 2016 Sep; 57(9):2126-32. PubMed ID: 26769297
[TBL] [Abstract][Full Text] [Related]
6. How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond.
Rimando J; McCurdy SR; Luznik L
Blood; 2023 Jan; 141(1):49-59. PubMed ID: 35405017
[TBL] [Abstract][Full Text] [Related]
7. Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation.
Qayed M; Watkins B; Gillespie S; Bratrude B; Betz K; Choi SW; Davis J; Duncan C; Giller R; Grimley M; Harris AC; Jacobsohn D; Lalefar N; Norkin M; Farhadfar N; Pulsipher MA; Shenoy S; Petrovic A; Schultz KR; Yanik GA; Waller EK; Langston A; Kean LS; Horan JT
Blood Adv; 2022 Feb; 6(3):746-749. PubMed ID: 34753172
[No Abstract] [Full Text] [Related]
8. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
[TBL] [Abstract][Full Text] [Related]
9. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
[TBL] [Abstract][Full Text] [Related]
10. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial.
Koura DT; Horan JT; Langston AA; Qayed M; Mehta A; Khoury HJ; Harvey RD; Suessmuth Y; Couture C; Carr J; Grizzle A; Johnson HR; Cheeseman JA; Conger JA; Robertson J; Stempora L; Johnson BE; Garrett A; Kirk AD; Larsen CP; Waller EK; Kean LS
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1638-49. PubMed ID: 24047754
[TBL] [Abstract][Full Text] [Related]
11. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.
Pidala J; Kim J; Alsina M; Ayala E; Betts BC; Fernandez HF; Field T; Jim H; Kharfan-Dabaja MA; Locke FL; Mishra A; Nishihori T; Ochoa-Bayona L; Perez L; Riches M; Anasetti C
Haematologica; 2015 Jul; 100(7):970-7. PubMed ID: 25840599
[TBL] [Abstract][Full Text] [Related]
12. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.
Raiola AM; Dominietto A; di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Varaldo R; Ghiso A; Gobbi M; Carella AM; Signori A; Galaverna F; Bacigalupo A
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1573-9. PubMed ID: 24910379
[TBL] [Abstract][Full Text] [Related]
13. Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch.
Al Malki MM; Gendzekhadze K; Yang D; Mokhtari S; Parker P; Karanes C; Palmer J; Snyder D; Forman SJ; Nademanee A; Nakamura R
Transplantation; 2020 May; 104(5):1070-1080. PubMed ID: 31449184
[TBL] [Abstract][Full Text] [Related]
14. Abatacept-based Graft-Versus-Host Disease Prophylaxis in Haplo-identical Hematopoietic Cell Transplant in a High-risk Cohort.
Raffa EH; Srinivasan A; Wall DA; Schechter T; Ali M; Krueger J; Chiang KY
J Pediatr Hematol Oncol; 2022 Oct; 44(7):383-387. PubMed ID: 35129143
[TBL] [Abstract][Full Text] [Related]
15. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
16. Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood.
Rodrigues CA; Rocha V; Dreger P; Brunstein C; Sengeloev H; Finke J; Mohty M; Rio B; Petersen E; Guilhot F; Niederwieser D; Cornelissen JJ; Jindra P; Nagler A; Fegueux N; Schoemans H; Robinson S; Ruggeri A; Gluckman E; Canals C; Sureda A; ;
Haematologica; 2014 Feb; 99(2):370-7. PubMed ID: 23935024
[TBL] [Abstract][Full Text] [Related]
17. Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning.
Malard F; Fürst S; Loirat M; Chevallier P; El-Cheikh J; Guillaume T; Delaunay J; Le Gouill S; Moreau P; Blaise D; Mohty M
Leukemia; 2013 Nov; 27(11):2113-7. PubMed ID: 23752174
[TBL] [Abstract][Full Text] [Related]
18. Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies.
Passweg JR; Zhang MJ; Rocha V; Kan F; Champlin RE; Isola LM; Gee AP; Gibson J; Laughlin MJ; Lazarus HM; Loren A; Marks DI; Gratwohl A; Eapen M
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1869-73. PubMed ID: 21771571
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
20. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
